Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2022 Jan 15;28:100849. doi: 10.1016/j.imu.2022.100849

Optimal control analysis of a COVID-19 and tuberculosis co-dynamics model

MS Goudiaby a,, LD Gning b, ML Diagne c, Ben M Dia d, H Rwezaura e, JM Tchuenche f
PMCID: PMC8759807  PMID: 35071729

Abstract

Tuberculosis and COVID-19 are among the diseases with major global public health concern and great socio-economic impact. Co-infection of these two diseases is inevitable due to their geographical overlap, a potential double blow as their clinical similarities could hamper strategies to mitigate their spread and transmission dynamics. To theoretically investigate the impact of control measures on their long-term dynamics, we formulate and analyze a mathematical model for the co-infection of COVID-19 and tuberculosis. Basic properties of the tuberculosis only and COVID-19 only sub-models are investigated as well as bifurcation analysis (possibility of the co-existence of the disease-free and endemic equilibria). The disease-free and endemic equilibria are globally asymptotically stable. The model is extended into an optimal control system by incorporating five control measures. These are: tuberculosis awareness campaign, prevention against COVID-19 (e.g., face mask, physical distancing), control against co-infection, tuberculosis and COVID-19 treatment. Five strategies which are combinations of the control measures are investigated. Strategy B which focuses on COVID-19 prevention, treatment and control of co-infection yields a better outcome in terms of the number of COVID-19 cases prevented at a lower percentage of the total cost of this strategy.

Keywords: Bifurcation, Co-infection, COVID-19, Optimal control, Reproduction number, Tuberculosis

1. Introduction

Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), one of the top ten leading causes of death due to a single disease worldwide [1]. The transmission route are through cough, sneeze, speak or spit from active pulmonary TB persons, it can also be spread through use of an infected person’s unsterilized eating utensils [2]. The chain of transmission could be broken by isolating and treating infectives [3].

On the other hand, COVID-19 caused by the coronavirus SARS-CoV-2 emerged in December 2019 [4], [5], [6], and spread worldwide like a wildfire [7]. The virus can spread from an infected person’s mouth or nose when they cough, sneeze, speak, sing or breathe. These similarities of COVID-19 spreading pattern and TB call for great attention [8]. While most people who fall sick with COVID-19 may experience mild to moderate symptoms and recover without special treatment, the pandemic has claim millions of lives. COVID-19 prevention interventions (non-therapeutic measures) such as wearing face masks, self-isolation, physical distancing, and the most restrictive lock-downs could affect the transmission dynamic of TB. With the combination of non therapeutic prevention interventions and therapeutic measures, the number of COVID-19 cases and deaths have reduced despite the emergence of new variants of the COVID-19 virus [9].

Geographical overlap of both diseases and their clinical similarities could be a double blow in mitigating their spread because of the potential fatal outcome if they are not properly diagnosed and adequately treated [8]. Co-infection of both diseases is inevitable given the high worldwide prevalence of TB and COVID-19 [10], [11], [12], [13]. Co-interaction of TB and COVID-19 may pose a challenge in mitigating their spread, as TB is a risk factor for COVID-19 both in terms of severity and mortality [14]. In fact, co-infection related mortality is higher (about 12.3%) in the patients with dual infection [15]. Also, COVID-19 patients have a low ability to build an immune response to TB, while in co-infected subjects, TB could impair the ability to mount a SARS-CoV-2 specific immune response [16]. These two diseases (TB and COVID-19) of global public health concern form a deadly duo, with great socio-economic impact worldwide [10]. From the aforementioned reasons, it is important to theoretically investigate the impact of control measures on their long-term dynamics.

We formulate and analyze a mathematical model for the co-infection of COVID-19 and TB transmission. Basic properties of the two sub-models, namely TB only and COVID-19 only) are investigated as well as the possibility of the co-existence of the disease-free and endemic equilibria (bifurcation analysis). Optimal control strategies are incorporated into the model, and conditions for the existence of optimal control and the optimality system for the co-infection model are established using the Pontryagin’s maximum Principle.

The paper is organized as follows. The proposed co-infection model is formulated in Section 2. The model and its sub-models, TB and COVID-19 are rigorously analyzed in Section 3. In order to mitigate the spread of these two diseases and their co-infection, time variant controls are introduced into the full model, and the obtained optimal control problem investigated via the Pontryagin’s Maximum Principle in Section 4. To support the theoretical results, numerical simulations are provided in Section NS, where five scenarios being combinations of various control strategies are investigated. Finally, Section 6 is the conclusion where it is noted that the best scenario in terms of the potential number of COVID-19 cases that could be prevented (at a lower percentage of the total cost) is Strategy B which focuses on COVID-19 prevention, treatment and control of co-infection.

2. The model

The population at time t denoted by N(t) is divided into sub-populations of susceptible individuals S(t), individuals exposed to COVID-19 only EC(t), unreported individuals infected with COVID-19 only ICU(t), reported individuals infected with COVID-19 only ICR(t), individuals exposed to tuberculosis only ET(t), unreported individuals infected with tuberculosis only ITU(t), reported individuals infected with tuberculosis only ITR(t), individuals exposed to tuberculosis and COVID-19 ECT(t), individuals infected with tuberculosis and COVID-19 ICT(t) and recovered individuals R(t). It is important to note that all exposed individuals herein are actually asymptomatic and can transmit either of the disease as per their disease status.

The model has the following assumptions:

  • i.

    individuals infected with COVID-19 are susceptible to infection with tuberculosis and vice versa.

  • ii.

    co-infected individuals can transmit either COVID-19 or tuberculosis but not the mixed infections at the same time,

  • iii.

    co-infected individuals can recover either from COVID-19 or tuberculosis but not from the mixed infection at the same time,

  • iv.

    rate of transmissibility for singly infected and co-infected individuals are assumed to be the same.

Individuals are recruited into the population through birth or immigration at the rate ωH. Susceptible humans S acquire COVID-19 following effective contacts with either singly or co-infected individuals with COVID-19 at the rate

λC=ΛC(EC+ICU)N. (1)

Similarly, the population S, is reduced due to infection with tuberculosis at the rate

λT=ΛTITUN. (2)

From the model flow diagram in Fig. 1 and the above description, we derive the following nonlinear system ordinary differential equations for the COVID-19 and tuberculosis co-infection.

dSdt=ωH+ωRRλCSλTSμHS,dECdt=λCSβCλCEC(ηR+ηU)ECμHEC,dICRdt=ηREC+αCICT(αCR+αC)ICR(μH+ϕCR)ICR,dICUdt=ηUEC(γCU+αCU)ICU(μH+ϕCU)ICU,dECTdt=βCλCEC+βTλTETγCTECTμHECT,dICTdt=γCTECT+γTUITU+γCUICU+αCRICR+αTRITR(αC+αT)ICT(μH+ϕCT)ICT,dETdt=λTS(βTλT+θU+θR)ETμHET,dITUdt=θUET(γTU+αTU)ITU(μH+ϕTU)ITU,dITRdt=θRET+αTICT(αTR+αT)ITR(μH+ϕTR)ITR,dRdt=αCICR+αCUICU+αTUITU+αTITRμHRωRR, (3)

together with initial conditions

S(0)0,EC(0)0,ET(0)0,ECT(0)0,ICR(0)0,ICU(0)0,ICT(0)0,ITU(0)0,ITR(0)0,R(0)0. (4)

Fig. 1.

Fig. 1

COVID-19 and tuberculosis co-interaction flow diagram.

3. Model analysis

Two sub-models, namely: Tuberculosis only and COVID-19 only sub-models will first be considered.

3.1. COVID-19 only sub-model

By setting ET=ECT=ICT=ITU=ITR=0, we obtain the following COVID-19 only sub-model.

dSdt=ωH+ωRRλCSμHS,dECdt=λCS(ηR+ηU+μH)EC,dICRdt=ηREC(αC+μH+ϕCR)ICR,dICUdt=ηUEC(αCU+μH+ϕCU)ICU,dRdt=αCICR+αCUICUμHRωRR, (5)

where NC=S+EC+ICR+ICU+R. By adding up all the equations of the system (5), we have

N˙C=ωHμHNCϕCRICRϕCUICUωHμHNC. (6)

The given initial conditions of the sub-model system (5) ensure that N(0)0. Thus, the total human population is positive and bounded for all finite time t>0. From the theory of differential inequality [31], we have

NC(t)NC(0)eμHt+ωHμH(1eμHt). (7)

As t+, we obtain 0NC(t)ωHμH. The feasible region of the COVID-19 only sub-model (5) is given by

ΩC=(S,EC,ICR,ICU,R)R+5:NC(t)ωHμH. (8)

The set Ωc is positively invariant and attracting [32], and all solutions of the COVID-19 only sub-model (5) starting in Ωc remain in Ωc for all t0. Thus, the model (5) is mathematically and epidemiologically well-posed, and it is sufficient to study its dynamics in Ωc [3], [33].

3.1.1. Stability of the disease-free equilibrium

The disease-free equilibrium (DFE) of the COVID-19 only sub-model system (5) is obtained when EC=ICR=ICU=R=0. Thus, the DFE of the COVID-19 only sub-model (5) is given by

EC0=(S0,EC0,ICR0,ICU0,R0)=(ωHμH,0,0,0,0). (9)

The linear stability of EC0 is established using the next generation operator method on system (5) as described in [34]. System (5) can be written as

x˙=f(x)=F(x)V(x), (10)

where

F=λCS00,

and

V=(ηR+ηU+μH)ECηREC+(αC+μH+ϕCR)ICRηUEC+(αCU+μH+ϕCU)ICU.

are the new infection and transfer terms respectively. Evaluating the Jacobian of F and V at the DFE EC0 gives

F=ΛC0ΛC000000,

and

V=ηR+ηU+μH00ηRαC+μH+ϕCR0ηU0αCU+μH+ϕCU.

Set

A1=ηR+ηU+μH,A2=αC+μH+ϕCRandA3=αCU+μH+ϕCU. (11)

The inverse of the matrix V is given by

V1=1A100ηRA1A21A20ηUA1A301A3.

The largest eigenvalue of the next generation matrix FV1 denoted by R0C is given by

R0C=ΛCηUA1A3+ΛCA1=ΛC(ηU+αCU+μH+ϕCU)(ηR+ηU+μH)(αCU+μH+ϕCU). (12)

The basic reproduction number R0C is defined as the expected number of secondary cases generated by one infected individual during its entire period of infectiousness in a fully susceptible population [34]. From Theorem 2 of [34], the following result follows.

Lemma 3.1

The disease-free equilibrium EC0 of the COVID-19 only sub-model system (5) is locally asymptotically stable if R0C<1 , and unstable otherwise.

Proof

The stability of EC0 is obtained from the roots of the characteristic polynomial, which states that the equilibrium is stable if the roots of the characteristic polynomial are all negative. For EC0, the Jacobian matrix of the system is obtained as

J(EC0)=μHΛC0ΛCωR0ΛCA10ΛC00ηRA2000ηU0A3000αCαCU(μH+ωR).

where Ai;i=1,2,3 are given in (11). The characteristic polynomial is given by

P(λ)=(λ+μH)(λ+μH+ωR)(λA2)((λ+ΛCA1)(λA3)ΛCηU)=(λ+μH)(λ+μH+ωR)(λA2)(λ2+λ(A1ΛC+A3)+A1A3ΛCA3ΛCηU). (13)

Using the Routh–Hurwitz criterion for second order polynomials, we have for ΛC<ηR+ηU+μH and R0C<1 that A1ΛC+A3 and A1A3ΛCA3ΛCηU are positive. Hence all eigenvalues are negative which means that the DFE EC0 of the COVID-19 only sub-model system (5) is locally asymptotically stable when R0C<1. ■

Theorem 3.1

The DFE of the COVID-19 only model (5) is globally asymptotically stable for if R0C<1 .

Proof

Consider the following Lyapunov function

W=(αCU+μH+ϕCU)EC+ΛCICU.

The time derivative of W computed along the solutions of (5) is given by

W˙=(αCU+μH+ϕCU)E˙C+ΛCI˙CU,=(αCU+μH+ϕCU)λCS(ηR+ηU+μH)EC+ΛCηUEC(αCU+μH+ϕCU)ICU,=(αCU+μH+ϕCU)ΛC(EC+ICU)NS(ηR+ηU+μH)EC+ΛCηUEC(αCU+μH+ϕCU)ICU,(αCU+μH+ϕCU)ΛC(EC+ICU)(ηR+ηU+μH)EC+ΛCηUEC(αCU+μH+ϕCU)ICU,(αCU+μH+ϕCU)ΛCEC(ηR+ηU+μH)(αCU+μH+ϕCU)EC+ΛCηUEC,ΛC(αCU+μH+ϕCU+ηU)EC(ηR+ηU+μH)(αCU+μH+ϕCU)EC,(ηR+ηU+μH)(αCU+μH+ϕCU)EC(R0C1),0, for R0C1.

Because all model parameters are non-negative, it follows that W˙0 for R0C1, with W˙=0 if and only if EC=ICR=ICU=0. Substituting (EC,ICR,ICU)=(0,0,0) into 3.1 shows that SΠHαH as t. Hence, W is a Lyapunov function on Ωc and the largest compact invariant set in {(S,EC,ICR,ICU,R)Ωc:W˙=0} is Ec. Thus, by LaSalle’s invariance principle, every solution of (5), with initial conditions in Ωc approaches Ec, as t whenever R0C1. ■

3.1.2. Stability of the endemic equilibrium

We explore the stability of the endemic equilibrium of the COVID-19 only sub-model system (5) given by

EC1=(SC1,ECC1,ICRC1,ICUC1,RC1),=ωHλC+μH,ωHλC(λC+μH)A1,ωHλCηR(λC+μH)A1A2,ωHλCηU(λC+μH)A1A3,ωHλC(αCηRA3+αCUηUA2)μH(λC+μH)A1A2A3, (14)

where

λC=ΛC(ECC1+ICUC1)SC1+ECC1+ICRC1+ICUC1+RC1. (15)

Note that

ECC1+ICUC1=ωHλCA2(A3+ηU)μH(λC+μH)A1A2A3. (16)

Also,

SC1+ECC1+ICRC1+ICUC1+RC1=λCA2A3+ηRA31+αCμH+ηUA21+αCUμH+A1A2A3μH(λC+μH)A1A2A3. (17)

Substituting Eqs. (16), (18) into (15), we obtain

λCA2A3+ηRA31+αCμH+ηUA21+αCUμH=A2A1A3R0C1. (18)

Therefore, λC exists if and only if R0C>1. Hence, the following result.

Theorem 3.2

The COVID-19 only model system (5) has a unique endemic equilibrium if R0C>1 .

In the following, we use the center manifold approach to analyze the global stability of the full model. To this end we use the notation: x1=S, x2=EC, x3=ICR, x4=ICU, x5=R and NC=x1+x2+x3+x4+x5 to write the model in the form x˙=f(x) with x=(x1,,x5)T and f=(f1,,f5). That is

x˙1=f1=ωH+ωRx5ΛC(x2+x4)x1+x2+x3+x4+x5x1μHx1,x˙2=f2=ΛC(x2+x4)x1+x2+x3+x4+x5x1(ηR+ηU+μH)x2,x˙3=f3=ηRx2(αC+αCR+μH+ϕCR)x3,x˙4=f4=ηUx2(γCU+αCU+μH+ϕCU)x4,x˙5=f5=αCx3+αCUx4(μH+ωR)x5, (19)

The Jacobian of (19) at the DFE EC0 is given by

J(EC0)=μHΛC0ΛC00ΛCA10ΛC00ηRA2000ηU0A3000αCαCUμH,

where Ai;i=1,2,3 are given in Eq. (11).

We choose ΛC as a bifurcation parameter. Therefore, setting R0C=1, we obtain

ΛC=ΛC=(ηR+ηU+μH)(αCU+μH+ϕCU)(ηU+αCU+μH+ϕCU). (20)

At ΛC=ΛC, the Jacobian has a simple zero eigenvalue (since A1A3ΛCA3ΛCηU=0, see Eq. (13)) and all other eigenvalues have negative real parts. Therefore, the DFE EC0 is a non-hyperbolic equilibrium point. Hence, the center manifold theory [35] can be applied to model system (19) near ΛC=ΛC.

The right eigenvector w=(w1,w2,w3,w4,w5)T associated with the zero eigenvalue of J(EC0) evaluated at ΛC=ΛC is

w1=(ωRμH+ωRαCηRμHA2+αCUηUμHA3A1μH)w2,w3=ηRA2w2,w4=ηUA3w2,w5=1μH+ωRαCηRA2+αCUηUA3w2,w2=w2>0. (21)

Similarly, the left eigenvector v=(v1,v2,v3,v4,v5) is given by

v1=0,v3=0,v5=0,v4=A1ηU+A3v2,v2=v2>0. (22)

The left and right eigenvectors satisfy v.w=1 that is

v2w21+ηUA1(ηU+A3)A3=1. (23)

For the direction of the bifurcation, we determine the sign of the bifurcation parameters a and b. For a, one has

a=k,i,j=15vkwiwj2fkxixj(EC0,ΛC),=i,j=15v2wiwj2f2xixj(EC0,ΛC). (24)

The partial derivatives are

f2x1=λCλCx1NC,f2x2=(ΛCλC)x1NC,f2x3=λCx1NC,f2x4=(ΛCλC)x1NC,f2x5=λCx1NC. (25)

Therefore,

a=μHΛCωHv2(w1w2+w1w4w22w2w3w2w4w2w5w4w2w4w3w42w4w5). (26)

On the other hand, we have

w1=(ωRμH+ωRαCηRμHA2+αCUηUμHA3A1μH)w2,αCηRμHA2+αCUηUμHA3A1μHw21μHαCA21ηR+αCUA31ηUμHw2δw2. (27)

with

δ=1μH1αCA2ηR+1αCUA3ηU+μH>0 (28)

Taking into account (27) in (29), the bifurcation parameter a satisfies :

aμHΛCωHv2(δw22+δw2w4+w22+w2w3+w2w4+w2w5+w4w2+w4w3+w42+w4w5),0. (29)

For the bifurcation parameter b, we have

b=k,j=15vkwj2fkxjΛC(EC0,ΛC),=j=15v2wj2f2xjΛC(EC0,ΛC),=v2w2+v2w4,=v2w21+ηUA3>0. (30)

Since a<0 and b>0, the COVID-19 only sub-model system (5) does not exhibit the phenomenon of backward bifurcation at R0C=1. Because the direction of the bifurcation is forward (transcritical bifurcation), a stable disease-free equilibrium cannot co-exist with a stable endemic equilibrium. Similar result for the COVID-19 only model was obtained in [36], [37]. Hence, the following result.

Theorem 3.3

The unique endemic equilibrium EC1 of the COVID-19 only sub-model (5) is globally asymptotically stable if R0C>1 .

The above result when R0C>1 is graphically depicted in Fig. 2. The red line in Fig. 2 represents the area of instability of the endemic equilibrium EC1, and the blue line the stability area of the endemic equilibrium EC1. The red dotted line represents the threshold stability switch line R0C=1. When R0C>1, the green line does not cross the dotted line, hence the endemic equilibrium EC1 is globally asymptotically stable.

Fig. 2.

Fig. 2

Illustration of the bifurcation by plotting ΛC versus R0C.

3.2. Tuberculosis only sub-model

The following tuberculosis only sub-model is obtained from system (3) when EC=ECT=ICT=ICU=ICR=0.

dSdt=ωHλTSμHS,dETdt=λTS(θU+θR+μH)ET,dITUdt=θUET(αTU+μH+ϕTU)ITU,dITRdt=θRET(αT+μH+ϕTR)ITR,dRdt=αTUITU+αTITRμHR, (31)

where NT=S+ET+ITR+ITU+R.

Arguing as in 3, the feasible region for the tuberculosis only sub-model

ΩT=(S,ET,ITU,ITR,R)R+5:NT(t)ωHμH. (32)

is positively invariant and attracting, that is, solution starting in ΩT will remain in ΩT for all time t0. Thus, it is sufficient to consider the dynamics of the sub-model system (31) in ΩT.

3.2.1. Stability of the disease-free equilibrium

The DFE of the tuberculosis only sub-model (31) is

ET0=(S0,ET0,ITU0,ITR0,R0)=(ωHμH,0,0,0,0). (33)

The basic reproductive number R0T is derived using the next generation operator method [34].

The sub-model system (31) can be written as

x˙=f(x)=F(x)V(x), (34)

where

F=λTS00,

and

V=(θR+θU+μH)ETθUET+(αTU+μH+ϕTU)ITUθRET+(αT+μH+ϕTR)ITR

are the new infection and transfer terms respectively. Evaluating the Jacobian of F and V at the DFE ET0 gives

F=0ΛT0000000,

and

V=θR+θU+μH00θUαTU+μH+ϕTU0θR0αT+μH+ϕTR.

Set

B1=θR+θU+μH,B2=αTU+μH+ϕTUandB3=αT+μH+ϕTR. (35)

The inverse of the matrix V is

V1=1B100θUB1B21B20θRB1B301B3.

Therefore, the basic reproduction number R0T which is the largest eigenvalue or spectral radius of the next generation matrix FV1 is given by

R0T=ΛTθUB1B2=ΛTθU(θR+θU+μH)(αTU+μH+ϕTU). (36)

The basic reproduction number R0T represents the average number of cases directly generated by one infectious TB case in a population which is assumed totally susceptible [38].

Thus, using Theorem 2 of [34], we establish the following result.

Theorem 3.4

The DFE of the tuberculosis only sub-model (31) is locally asymptotically stable if R0T<1 , and unstable otherwise.

Proof

For ET0, the Jacobian matrix of the system is obtained as

J(ET0)=μH0ΛT0ωR0B1ΛT000θUB2000θR0B3000αTUαTμHωR,

where Bi;i=1,2,3 are given in Eq. (35). The characteristic polynomial is given by

P(λ)=(λ+μH)(λ+μH+ωR)(λB3)((λB1)(λB2)ΛTθU),=(λ+μH)(λ+μH+ωR)(λB3)(λ2+λ(B1+B2)+B1B2ΛTθU). (37)

The eigenvalues of the characteristic polynomial (37) are μH,μHωR,B3,

(B1+B1)(B1B1)2+4ΛTθUand(B1+B1)+(B1B1)2+4ΛTθU.

The first four eigenvalues are negative, and since R0T<1 the last one is also negative. Hence, the DFE ET0 of the tuberculosis only sub-model system (31) is locally asymptotically stable when R0T<1. ■

Theorem 3.5

The DFE of the tuberculosis only sub-model (31) is globally asymptotically stable if R0T<1 , and unstable otherwise.

Proof

Consider the following Lyapunov function

W=(αTU+μH+ϕTU)ET+ΛTITU.

The time derivative of W computed along the solutions of (31) is given by

W˙=(αTU+μH+ϕTU)E˙T+ΛTI˙TU,=(αTU+μH+ϕTU)λTS(θR+θU+μH)EC+ΛTθUET(αTU+μH+ϕTU)ITU,=(αTU+μH+ϕTU)ΛTICUNS(θR+θU+μH)ET+ΛTθUET(αTU+μH+ϕTU)ITU,(αTU+μH+ϕTU)ΛTITU(θR+θU+μH)ET+ΛTθUET(αTU+μH+ϕTU)ITU,(αTU+μH+ϕTU)(θR+θU+μH)ET+ΛTθUET,(αTU+μH+ϕTU)(θR+θU+μH)ET(R0T1),0, for R0T1.

Because all model parameters are non-negative, it follows that W˙, for R0T1 with W˙=0 if and only if ET=ITR=ITU=0. Substituting (ET,ITR,ITU)=(0,0,0) into (31) shows that SωHαH as t. Hence, W is a Lyapunov function on ΩT, and the largest compact invariant set in {(S,ET,ITR,ITU,R)ΩT:W˙=0} is ET. Thus, by LaSalle’s invariance principle, every solution of (31), with initial conditions in ΩT approaches ET, as t whenever R0T1. ■

3.2.2. Stability of the endemic equilibrium

We study the stability of the endemic equilibrium of the tuberculosis only sub-model system (31). From (5), this equilibrium denoted by ET1 is given by

ST1=ωH(ωR+μH)B1B2B3(λT+μH)(ωR+μH)B1B2B3λTωR(αTθRB2+αTUθUB3),ETT1=ωHλT(ωR+μH)B2B3(λT+μH)(ωR+μH)B1B2B3λTωR(αTθRB2+αTUθUB3),ITUT1=ωHλTθU(ωR+μH)B3(λT+μH)(ωR+μH)B1B2B3λTωR(αTθRB2+αTUθUB3),ITRT1=ωHλTθR(ωR+μH)B2(λT+μH)(ωR+μH)B1B2B3λTωR(αTθRB2+αTUθUB3),RT1=ωHλT(αTθRB2+αTUθUB3)(λT+μH)(ωR+μH)B1B2B3λTωR(αTθRB2+αTUθUB3), (38)

where

λT=ΛTITUT1ST1+ETT1+ITUT1+ITRT1+RT1=ΛTITUT1NT1,=ΛTωHλTθU(ωR+μH)B3NT1(λT+μH)(ωR+μH)B1B2B3λTωR(αTθRB2+αTUθUB3) (39)

Note that NT1 given in Box I.

Box I.
NT1=ωHλT((ωR+μH)B2B3+θRB2ωR+μH+αT+θUB3ωR+μH+αTU)+ωH(ωR+μH)B1B2B3(λT+μH)(ωR+μH)B1B2B3λTωR(αTθRB2+αTUθUB3) (40)

Substituting (40) into (39), we obtain

λT((ωR+μH)B2B3+θRB2ωR+μH+αT+θUB3ωR+μH+αTU)=(ωR+μH)B1B2B3R0T1. (41)

Therefore, λT exist if and only if R0T>1. Hence, we have established the following result.

Theorem 3.6

The tuberculosis only sub-model system (31) has one unique endemic equilibrium if R0T>1 .

We again use the center manifold approach to analyze the global stability of the tuberculosis only sub-model (31). To this end, we use the notation x1=S, x2=EC, x3=ICT, x4=ICR, x5=R and NT=x1+x2+x3+x4+x5 to write the model in the form x˙=f(x), with x=(x1,,x5)T and f=(f1,,f5) as follows

x˙1=f1=ωH+ωRx5ΛTx3x1+x2+x3+x4+x5x1μHx1,x˙2=f2=ΛTx3x1+x2+x3+x4+x5x1(θR+θU+μH)x2,x˙3=f3=θUx2(αTU+μH+ϕTU)x3,x˙4=f4=θRx2(αT+μH+ϕTR)x4,x˙5=f5=αTUx3+αTx4(μH+ωR)x5, (42)

The Jacobian of (42) at the DFE ET0 is

J(ET0)=μH0ΛT0ωR0B1ΛT000θUB2000θR0B3000αTUαTμHωR,

where Bi;i=1,2,3 are given in Eq. (35). We choose ΛT as a bifurcation parameter. Therefore, setting R0T=1, we obtain

ΛT=ΛT=B1B2θU=(θR+θU+μH)(αTU+μH+ϕTU)θU. (43)

At ΛT=ΛT the Jacobian has a simple zero eigenvalue and all other eigenvalues have negative real parts. Therefore, the disease free equilibrium point ET0 is a non-hyperbolic equilibrium point. Hence, the center manifold theory can be applied to model system (42) near ΛT=ΛT.

The right eigenvector w=(w1,w2,w3,w4,w5)T associated with the zero eigenvalue of J(ET0) evaluated at ΛT=ΛT is

w1=ωRμH+ωRαTθRμHB3+αTUηUμHB2w2B1μHw2,w3=θUB2w2,w4=θRB3w2,w5=1μH+ωRαTθRB3+αTUηUB2w2,w2=w2>0. (44)

Similarly, the left eigenvector v=(v1,v2,v3,v4,v5) is given by

v1=0,v4=0,v5=0,v3=B1θUv2,v2=v2>0. (45)

The left and right eigenvectors satisfy v.w=1, that is,

v2w21+B1B2=1. (46)

For the direction of the bifurcation, we determine the sign of the bifurcation parameters a et b.

a=k,i,j=15vkwiwj2fkxixj(ET0,ΛT)=i,j=15v2wiwj2f2xixj(ET0,ΛT). (47)

The partial derivatives are

f2x1=λTλTx1NT,f2x2=λTx1NT,f2x3=(ΛTλT)x1NT,f2x4=λTx1NT,f2x5=λTx1NT. (48)

Therefore,

a=μHΛTωHv2(w1w3+w3w2w33w3w4w3w5),=μHΛTωHθUB2v2w22B1μHθUB2θRB3αTθRμHB3αTUηUμHB21,=μHB1ωHv2w22B1μH+θUB2+θRB3+αTθRμHB3+αTUηUμHB2+1<0. (49)

For the bifurcation parameter b, we have

b=k,j=15vkwj2fkxjΛT(ET0,ΛT),=j=15v2wj2f2xjΛT(ET0,ΛT),=v2w3,=θUB2v2w2>0. (50)

Since a<0 and b>0, our proposed tuberculosis only sub-model system (31) does not exhibit the phenomenon of backward bifurcation at R0T=1. Hence, the following result.

Theorem 3.7

The unique endemic equilibrium ET1 of the tuberculosis only sub-model (31) is globally asymptotically stable if R0T>1 .

The above result when R0T>1 is graphically depicted in Fig. 3. The red line in Fig. 2 represents the stability area of the DFE ET0, and the blue line is the instability area of the DFE. The red dotted line represents the threshold stability switch line R0T=1. When R0T>1, the green line does not cross the dotted line, hence the endemic equilibrium ET1 is globally asymptotically stable.

Fig. 3.

Fig. 3

Illustration of the bifurcation by plotting ΛT versus R0T.

3.3. Tuberculosis-COVID-19 model

The feasible region of the full model system (3) is

ΩCT=ΩC×ΩT, (51)

where ΩC and ΩT are defined in (8), (32), respectively.

The DFE of the COVID-19 and tuberculosis co-infection model is given by

E0=(S0,EC0,ICR0,ICU0,ECT0,ICT0,ET0,ITU0,ITR0,R0)=(ωHμH,0,0,0,0,0,0,0,0,0). (52)

From the basic reproduction number of the COVID-19 only and tuberculosis only sub-models, the basic reproduction number of the full system is given as

R0CT=max(R0C,R0T), (53)

where R0C and R0T are respectively defined in (12), (36).

Using Theorem 2 of [34],

Theorem 3.8

The DFE of the tuberculosis–COVID-19 model (31) is locally asymptotically stable if R0CT<1 , and unstable otherwise.

Since the COVID-19 only and tuberculosis only sub-models do not undergo the phenomenon of backward bifurcation, the full tuberculosis–COVID-19 model will not undergo backward bifurcation.

4. Optimal control model

This section is devoted to investigating optimal interventions for mitigating the spread of COVID-19 and tuberculosis and their co-infection. We incorporate the following five controls into the full model (3)

  • u1: Public awareness campaign control of tuberculosis,

  • u2: Prevention control against COVID-19 (e.g., face mask, physical distancing),

  • u3: Control against co-infection with a second disease,

  • u4: Tuberculosis treatment control, and

  • u5: COVID-19 treatment control.

The model system (3) now reads

dSdt=ωH+ωCUICU+ωCRICR+ωTUITU+ωTRITR+ωCTICT(1u2)λCS(1u1)λTSμHS,dECdt=(1u2)λCS(1u3)βCλCEC(ηR+ηU)ECμHEC,dICRdt=ηREC+(1+u5)αCICT(ωCR+αCR+(1+u5)αC)ICR(μH+ϕCR)ICR,dICUdt=ηUEC(ωCU+γCU+αCU)ICU(μH+ϕCU)ICU,dECTdt=(1u3)βCλCEC+(1u3)βTλTETγCTECTμHECT,dICTdt=γCTECT+γTUITU+γCUICU+αCRICR+αTRITR(ωCT+(1+u5)αC+(1+u4)αT)ICT(μH+ϕCT)ICT,dETdt=(1u1)λTS(1u3)βTλTET(θU+θR)ETμHET,dITUdt=θUET(ωTU+γTU+αTU)ITU(μH+ϕTU)ITU,dITRdt=θRET+(1+u4)αTICT(ωTR+αTR+(1+u4)αT)ITR(μH+ϕTR)ITR,dRdt=(1+u5)αCICR+αCUICU+αTUITU+(1+u4)αTITRμHR, (54)

with initial conditions

S(0)0,EC(0)0,ET(0)0,ECT(0)0,ICR(0)0,ICU(0)0,ICT(0)0,ITU(0)0,ITR(0)0,R(0)0. (55)

In what follows, because the positive balancing cost factors transfer the integral into monetary quantity over a finite period of time, we choose a quadratic control function, see [36] and the references therein. Thus, consider the following quadratic objective functional which measures the cost of the control. This cost includes strategies and treatment for mitigating at the population level the spread of COVID-19 and tuberculosis, as well as their co-infection. Thus, the nonlinear objective function is

J(u1,u2,u3,u4,u5)=0T[c1EC(t)+c2ECT(t)+c3ET(t)+c4ICU(t)+c5ITU(t)+c6ICR(t)+c7ICT(t)+c8ITR(t)+w12u12+w22u22+w32u32+w42u42+w52u52]dt, (56)

where T is the final time, ci,i=1,,8 are positive weight constants, and wi,i=1,,5 are weight constants for the strategies and treatments against proliferation of the COVID-19 and tuberculosis. The linear and quadratic form of the controls in (54) and in the objective function allow for the Hamiltonian associated to the optimal control problem to be maximized. Therefore, we seek to find, using the maximum principle of Pontryagin [39], an optimal control (u1,u2,u3,u4,u5)U satisfying (54), such that

J(u1,u2,u3,u4,u5)=min{J(u1,u2,u3,u4,u5)|(u1,u2,u3,u4,u5)U}. (57)

The associated pseudo-Hamiltonian is

H=c1EC(t)+c2ECT(t)+c3ET(t)+c4ICU(t)+c5ITU(t)+c6ICR(t)+c7ICT(t)+c8ITR(t)+w12u12+w22u22+w32u32+w42u42+w52u52+ξ1(ωH+ωCUICU+ωCRICR+ωTUITU+ωTRITR+ωCTICT(1u2)λCS(1u1)λTSμHS)+ξ2((1u2)λCS(1u3)βCλCEC(ηR+ηU)ECμHEC)+ξ3(ηREC+(1+u5)αCICT(ωCR+αCR+(1+u5)αC)ICR(μH+ϕCR)ICR)+ξ4(ηUEC(ωCU+γCU+αCU)ICU(μH+ϕCU)ICU)+ξ5((1u3)βCλCEC+(1u3)βTλTETγCTECTμHECT)+ξ6(γCTECT+γTUITU+γCUICU+αCRICR+αTRITR(ωCT+(1+u5)αC+(1+u4)αT)ICT(μH+ϕCT)ICT)+ξ7((1u1)λTS(1u3)βTλTET(θU+θR)ETμHET)+ξ8(θUET(ωTU+γTU+αTU)ITU(μH+ϕTU)ITU)+ξ9(θRET+(1+u4)αTICT(ωTR+αTR+(1+u4)αT)ITR(μH+ϕTR)ITR)+ξ10((1+u5)αCICR+αCUICU+αTUITU+(1+u4)αTITRμHR), (58)

where ξi,i=1,,10 are the adjoint variables satisfying

ξ1=HSξ2=HEC,ξ3=HICRξ4=HICU,ξ5=HECTξ6=HICT,ξ7=HETξ8=HITU,ξ9=HITRξ10=HR. (59)

Writing (61) in details gives

ξ˙1=(1u2)λC(ξ1ξ2)1SN+(1u1)λT(ξ1ξ7)1SN+(1u3)βCλC(ξ5ξ2)ECN+(1u3)βTλTξ5ξ7ETN+μHξ1,ξ˙2=(1u2)(ΛCλC)(ξ1ξ2)SN+(1u1)λT(ξ7ξ1)SN+(1u3)βC(ΛCλC)(ξ2ξ5)ECN+(1u3)βCλC(ξ2ξ5)+(1u3)βTλTξ5ξ7ETN+(ξ2ξ3)ηR+(ξ2ξ4)ηU+μHξ2c1,ξ˙3=(1u2)λC(ξ2ξ1)SN+(1u1)λT(ξ7ξ1)SN+(1u3)βCλC(ξ5ξ2)ECN+(μH+ϕCR)ξ3+(1u3)βTλTξ5ξ7ETN+αCR(ξ3ξ6)+ωCR(ξ3ξ1)+(1+u5)αC(ξ3ξ10)c6,ξ˙4=(1u2)(ΛCλC)(ξ1ξ2)SN+(1u1)λT(ξ7ξ1)SN+(1u3)βC(ΛCλC)(ξ2ξ5)ECN+(1u3)βTλTξ5ξ7ETN+αCU(ξ4ξ10)+ωCU(ξ4ξ1)+γCU(ξ4ξ6)+(μH+ϕCU)ξ4c4,ξ˙5=(1u2)λC(ξ2ξ1)SN+(1u1)λT(ξ7ξ1)SN+(1u3)βCλC(ξ5ξ2)ECN+(1u3)βTλTξ5ξ7ETN+γCT(ξ5ξ6)+μHξ5c2,ξ˙6=(1u2)λC(ξ2ξ1)SN+(1u1)λT(ξ7ξ1)SN+(1u3)βCλC(ξ5ξ2)ECN+(μH+ϕCT)ξ6+(1u3)βTλTξ5ξ7ETN+(1+u5)αC(ξ6ξ3)+(1+u4)αT(ξ6ξ9)+ωCT(ξ6ξ1)c7,ξ˙7=(1u2)λC(ξ2ξ1)SN+(1u1)λT(ξ7ξ1)SN+(1u3)βCλC(ξ5ξ2)ECN+(1u3)βTλTξ5ξ7ETN+(1u3)βTλTξ7ξ5+θR(ξ7ξ9)+θU(ξ7ξ8)+μHξ7c3,ξ˙8=(1u2)λC(ξ2ξ1)SN+(1u1)(ΛTλT)(ξ1ξ7)SN+(1u3)βCλC(ξ5ξ2)ECN+(μH+ϕTU)ξ8+(1u3)βT(ΛTλT)ξ7ξ5ETN+αTU(ξ8ξ10)+ωTU(ξ8ξ1)+γTU(ξ8ξ6)c5,ξ˙9=(1u2)λC(ξ2ξ1)SN+(1u1)λT(ξ7ξ1)SN+(1u3)βCλC(ξ5ξ2)ECN+(μH+ϕTR)ξ9+(1u3)βTλTξ5ξ7ETN+αTR(ξ9ξ6)+ωTR(ξ9ξ1)+(1+u4)αT(ξ9ξ10)c8,ξ˙10=(1u2)λC(ξ2ξ1)SN+(1u1)λT(ξ7ξ1)SN+(1u3)βCλC(ξ5ξ2)ECN+(1u3)βTλTξ5ξ7ETN+μHξ10, (60)

with the final conditions ξi(T),i=1,,10.

The necessary and sufficient optimality conditions are

Hu1=0,Hu2=0,Hu3=0,Hu4=0andHu5=0, (61)

which in turns give the optimal controls

u1=max0,min1,(ξ7ξ1)λTSw1,u2=max0,min1,(ξ2ξ1)λCSw2,u3=max0,min1,(ξ5ξ2)βCλCEC+(ξ5ξ7)βTλTETw3,u4=max0,min1,(ξ6ξ9)αTICT+(ξ9ξ10)αTITRw3,u5=max0,min1,(ξ6ξ3)αCICT+(ξ3ξ10)αCICRw3. (62)

5. Numerical simulations

To support the analytical results, the optimal control model system 4 is simulated using the model parameter values in Table 1. The positive weight constant w1=w2=w3=w4=w5=2.

Table 1.

Description of the variables and parameters.

Parameter Interpretation Value Reference
ωH Recruitment rate 1000059×365 [17], [18]
ωR Loss of immunity after recovery 0.1 Assumed
ΛC Effective contact rate transmission of COVID-19 0.6 [19]
ΛT Effective contact rate transmission of tuberculosis 1. 3 [20]
βC Modification parameter accounting for susceptibility of COVID-19-infected
Individuals to tuberculosis 1 Assumed
βT Modification parameter accounting for susceptibility of tuberculosis-infected
Individuals to COVID-19 1 Assumed
ηU Progression rate from asymptomatic to unreported symptomatic COVID-19 0. 785 [21]
ηR Progression rate from asymptomatic to reported symptomatic COVID-19 0. 2 [22]
θU Progression rate from exposed to unreported infectious tuberculosis class 0.7 [23]
θR Progression rate from exposed to reported infectious tuberculosis class 0.166 [23]
γCT Fraction of individuals moving to the co-infection class 0.0333 Assumed
αCR Tuberculosis infection rate of reported individuals already infected with COVID-19 0.0028 Assumed
γCU Tuberculosis infection rate of unreported individuals already infected with COVID-19 0.0044 Assumed
αTR COVID-19 infection rate of reported individuals already infected with tuberculosis 0.13 Assumed
γTU COVID-19 infection rate of unreported individuals already infected with tuberculosis 0.0333 Assumed
αCU Recovery rate of unreported COVID-19 infected individuals 0.142 [21]
αC Recovery rate of reported COVID-19 infected individuals 0.68 [24]
αTU Recovery rate of unreported tuberculosis infected individuals 0.175 [25]
αT Recovery rate of reported tuberculosis infected individuals 0.35 [25]
ϕCU Death rate of unreported COVID-19 infected individuals 0.0065 [26], [27]
ϕCR Death rate of reported COVID-19 infected individuals 0 .0018 [28]
ϕTU Death rate of unreported tuberculosis infected individuals 0. 004 [29]
ϕTR Death rate of reported tuberculosis infected individuals 0.000179 [30]
μH Natural death rate of the population 159×365 [17], [18]

To investigate the impact of various control strategies to mitigate the spread of both diseases, the following five scenarios are considered.

  • 1.

    Strategy A: COVID-19 prevention and treatment (u20,u50);

  • 2.

    Strategy B: COVID-19 prevention, treatment and control of co-infection (u20,u30,u50);

  • 3.

    Strategy C: Tuberculosis prevention and treatment (u10,u40));

  • 4.

    Strategy D: Tuberculosis prevention, treatment and control of co-infection (u10,u30,u40); and

  • 5.

    Strategy E: COVID-19 prevention with both TB and COVID-19 treatment (u20,u40,u50).

For all the five strategies, the reproduction number calculated using model parameter values in Table 1 is R0CT=max(R0C,R0T)=5.8038>1.

5.1. Strategy A: COVID-19 prevention and treatment (u20,u50)

Simulations of the optimal control system 4 when the strategy that prevents COVID-19 infection (u20) and the treatment of COVID-19 (u50) are implemented. The results of this strategy are shown in Figs. 4, 5, 6, Fig. 7, Fig. 8, respectively. When this intervention strategy is implemented, the number of symptomatic individuals not reported Icu drastically decreases, mainly due to the high disease (COVID-19-induced death rate reported in this class). Strategy A could reduce by 1,820 the number of new cases of reported COVID-19 (Fig. 5), and by 600 the number of new co-infections (Fig. 8). The control profiles depicted in Fig. 9 show that treatment is at optimal from the onset of the implementation and remain so throughout, while COVID-19 prevention drops at around 180 days for few days before picking up again. This drop likely corresponds to the relaxation of the COVID-19 prevention measures at the end of the first wave, while the sharp increase corresponds to the beginning of the second COVID-19 wave. For this strategy, we choose the positive weight constants c1=1.134,c2=1,c3=1,c4=2,c5=1,c6=2,c7=1,c8=1. Percentage estimation of the cost components of this Strategy A is as follows: unreported COVID-19 symptomatic 20% of the total cost of this strategy, reported symptomatic COVID-19 individuals 20%, co-infected 10%. This strategy does not reduce the number of people infected with tuberculosis as shown in Fig. 6, Fig. 7.

Fig. 4.

Fig. 4

Individuals Icu with strategy A.

Fig. 5.

Fig. 5

Individuals Icr with strategy A .

Fig. 6.

Fig. 6

Individuals Itr with strategy A .

Fig. 7.

Fig. 7

Individuals Itu with strategy A .

Fig. 8.

Fig. 8

Co-infected individuals Ict with strategy A.

Fig. 9.

Fig. 9

Control profile for strategy A.

Because the optimal control Figs. 4, 5, 6, Fig. 7, Fig. 8 are similar in the remaining strategies, we will only discuss the results without displaying the figures for the sake of avoiding redundancy of graphs.

5.2. Strategy B: COVID-19 prevention, treatment and control of co-infection (u20,u30,u50)

Simulations of the optimal control system 4 when the strategy that prevents COVID-19 infection (u20), the treatment of COVID-19 (u50) and control against co-infection (u30) are implemented. When this intervention strategy is implemented, it could reduce by 1,830 the number of new cases of reported COVID-19 Itr, and prevent about 615 the number of new co-infections. The number of symptomatic COVID-19 individuals not reported Icu decreases drastically due to the lack of treatment in this class. The control profiles in Fig. 10 show that prevention and treatment are optimal throughout the simulation period, while the control against co-infection is optimal from day 5 and will remain so up to 5 days before the duration of the simulation period. For this strategy, we choose the positive weight constants c1=1,c2=1,c3=1,c4=1,c5=1,c6=1,c7=1,c8=1. Percentage estimation of the cost components of Strategy B is as follows: both reported and unreported COVID-19 symptomatic as well as co-infected individuals 12.5% each. As in Strategy A, this strategy also does not reduce the number of people infected with tuberculosis.

Fig. 10.

Fig. 10

Control profile for strategy B.

5.3. Strategy C: Tuberculosis prevention and treatment (u10,u40))

Optimal control simulations for system 4 for Strategy C when tuberculosis prevention and treatment u10 and u40 are implemented. This Strategy C could reduce 2,515 new cases of reported tuberculosis Itr, and 90 new cases of co-infection. The control profiles in Fig. 11 shows that prevention is optimal throughout the simulation period, while treatment is optimal from day 22 through the remainder of the simulation period. For this strategy, we choose the positive weight constants c1=1,c2=1,c3=1,c4=1,c5=10,c6=1,c7=1,c8=1. Percentage estimation of the cost components Strategy C is as follows: unreported tuberculosis infected individuals 60% of the total cost of this strategy, reported tuberculosis infected and co-infected individuals 6% each. This strategy does not reduce the number of people infected with COVID-19.

Fig. 11.

Fig. 11

Control profile for strategy C.

5.4. Strategy D: Tuberculosis prevention, treatment and control of co-infection (u10,u30,u40)

Optimal control simulations for system 4 when the strategy for tuberculosis prevention (u10), the treatment of tuberculosis (u40), and control against co-infection (u30) are implemented. This strategy could reduce 2,510 new cases of reported tuberculosis Itr, and by 80 the number of new cases of co-infection. This strategy does not reduce the number of people infected with tuberculosis. The control profiles in Fig. 12 show that control against co-infection which starts approximately from day 10 is optimal throughout the simulation period. The prevention against tuberculosis is optimal from day 105, then decreases between days 154 and 169 (which likely coincides with the peak of COVID-19 first wave), then increases again from day 170. Tuberculosis treatment is optimal for the first 5 days of the simulations, then decreases between days 5 and 65 when we observe an increase that reaches the optimal on day 58. For this Strategy D, we choose the positive weight constants c1=5,c2=10,c3=5,c4=1,c5=14,c6=1,c7=4,c8=20. Percentage estimation of the cost components of this strategy is as follows: unreported tuberculosis infected individuals 25% of the total cost of this strategy, reported tuberculosis infected individuals 33.33%, and co-infection 6.66%.

Fig. 12.

Fig. 12

Control profile for strategy D.

5.5. Strategy E: COVID-19 prevention with both TB and COVID-19 treatment (u20,u40,u50)

Optimal control simulations for system 4 for COVID-19 prevention (u20), the treatment of tuberculosis and COVID-19 (respectively u40 and u50) are implemented. This strategy could potentially reduce by 1,520 the number of new cases of reported COVID-19 Icr, 300 new co-infection, and 800 new cases of infected and reported tuberculosis Itr. The control profiles in Fig. 13 show that prevention control of COVID-19 is optimal throughout the simulation period. The COVID-19 treatment is optimal for the first 7 days, then decreases drastically for 5 days and then remains optimal throughout the remainder of the simulation period. Treatment for tuberculosis begins around day 43 and remains at its optimum until the end of the simulation. For this Strategy E, we choose the positive weight constants c1=7,c2=6,c3=3.5,c4=3.3,c5=1,c6=10,c7=1,c8=1. Percentage estimation of the cost components of this strategy is as follows: The cost of mitigating the number of unreported COVID-19 infected individuals is 18% of the total cost, reported individuals COVID-19 infected 30%, while co-infection and reported individuals infected with tuberculosis is 3% each. This strategy does not reduce the number of people infected and unreported with tuberculosis.

Fig. 13.

Fig. 13

Control profile for strategy E.

The outcome of all these strategies are summarized in Table 2. Recall that the model variables in Table 2 are defined as follows:

  • .

    ICU(t) unreported individuals infected with COVID-19 only,

  • .

    ICR(t) reported individuals infected with COVID-19 only,

  • .

    ITU(t) unreported individuals infected with tuberculosis only,

  • .

    ITR(t) reported individuals infected with tuberculosis only, and

  • .

    ICT(t) co-infected individuals.

Table 2.

Summary of the optimal control strategies A - E.

Infections averted A B C D E
COVID-19 1,820 1,830
TB 2,515 2,510 300
Co-infection 600 615 90 80 800

% cost

ICU(t) 20% 12.5% 18%
ICR(t) 20% 12.5% 6% 6.6% 30%
ICT(t) 10% 12.5% 3%
ITU(t) 60% 25%
ITR(t) 6% 33.33% 3%

6. Conclusion

We formulated and analyzed a deterministic compartmental model for the transmission dynamics of tuberculosis and COVID-19. Theoretical results show that for both the tuberculosis (31) and COVID-19 only (5) sub-models, the DFE of each sub-model is globally asymptotically stable when the associated basic reproduction numbers R0T and R0C are less than unity, unstable otherwise. From the bifurcation analysis (using the central manifold theory), co-existence of both the DFE and the endemic equilibrium is not possible, and consequently, the endemic equilibria of the sub-models are also globally asymptotically stable whenever R0C>1 and R0T>1. That is, the bifurcation parameters a<0 and b>0, and the DFE of the two sub-models exchanges their stability with the endemic equilibrium at the threshold R0C=1 (for the COVID-19 only sub-model (5)) and R0T=1 (for the tuberculosis only sub-model (31)).

The basic model is then extended to included five control measures. The appropriate conditions for the existence of optimal control and the optimality system for the full model are established using Pontryagin’s maximum principle. To support the analytical results, numerical simulations of the model with optimal control are carried out using model parameters from the literature (Table 1).

Five strategies which are a combination of these control measures are investigated. Strategies A and B focus on COVID-19 mitigation, and from Table 2, Strategy B will prevent more COVID-19 and co-infections than Strategy A at a lowest total cost percentage (respectively 2,445; 38% vs 2,420; 50%). Similarly, Strategies C and D focus on TB mitigation. Strategy C will prevent 15 more infections than Strategy D, but at the expense of 7% higher percentage of the total cost of the intervention (2,605; 72% vs 2.590; 65%). Strategy E focuses on both COVID-19 and tuberculosis, and will prevent the least number of infections, 1,110 at 54% of the total cost. Because Strategies C and D focus on tuberculosis mitigation, the results suggest that during the course of the COVID-19 pandemic, Strategy B is a better option compared to Strategies A and E, while Strategies C, D and E will also come at a higher cost. As the COVID-19 pandemic is still ongoing, the best strategy of interest to health policy and decision-makers to mitigate its spread is Strategy B which focuses on COVID-19 prevention, treatment and control of co-infection. This strategy yields a better outcome in terms of the number of COVID-19 cases prevented at a lower percentage of the total cost.

The proposed model can be extended in several ways by (1) incorporating vaccination against COVID-19 and tuberculosis (2) inflow of infective immigrants (3) exogenous TB re-infection and COVID-19 re-infection after recovery (as several variants have recently emerged), (4) Generally, representations of real-life situations will inherit the loss of information, and sensitivity analysis is warranted. Also, investigating the impact of reducing the transmission rate and speeding up the time to detect infected individual [40].

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

  • 1.World Health Organization . 2021. Tuberculosis keys facts. http://www.https://www.who.int/en/news-room/fact-sheets/detail/tuberculosis. [Google Scholar]
  • 2.Cole E., Cook C. Characterization of infectious aerosols in health care facilities: An aid to effective engineering controls and preventive strategies. Am J Infect Control. 1998;26:453–464. doi: 10.1016/S0196-6553(98)70046-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Mtisi E., Rwezaura H., Tchuenche J.M. A mathematical analysis of malaria and tuberculosis co-dynamics. Discrete Contin Dyn Syst Ser B. 2009;12(4):827–864. [Google Scholar]
  • 4.Zu Na., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Andersen K.G., Rambaut A., Lipkin W.I., et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450–452. doi: 10.1038/s41591-020-0820-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Wu F., Zhao S., Yu B., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269. doi: 10.1038/s41586-020-2008-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.World Health Organization . 2021. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/ [Google Scholar]
  • 8.Vanzetti C.P., Salvo C.P., Kuschner P., Brusca S., Solveyra F., Vilela A. Tuberculosis and COVID-19 coinfection. Medicina (B Aires) 2020;80(6):100–103. [PubMed] [Google Scholar]
  • 9.Swan D.A., Bracis C., Janes H., et al. COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. Sci Rep. 2021;11:15531. doi: 10.1038/s41598-021-94719-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Khurana A.K., Aggarwal D. The (in)significance of TB and COVID-19 co-infection. Eur Respir J. 2020;56 doi: 10.1183/13993003.02105-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Motta I., Centis R., D’Ambrosio L., et al. Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology. 2020;26:233–240. doi: 10.1016/j.pulmoe.2020.05.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Stochino C., Villa S., Zucchi P., Parravicini P., Gori A., Raviglione M.C. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J. 2020;56(1) doi: 10.1183/13993003.01708-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Tadolini M., Codecasa L.R., Garcia-Garcia J.M., et al. Active tuberculosis, sequele and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020;56 doi: 10.1183/13993003.01398-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Tamuzi J.L., Ayele B.T., Shumba C.S., et al. Implications of COVID-19 in high burden countries for HIV/TB: a systematic review of evidence. BMC Infect Dis. 2020;20:744. doi: 10.1186/s12879-020-05450-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Petrone L., Petruccioli E., Vanini V., Cuzzi G., Gualano G., Vittozzi P., et al. Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. Int J Infect Dis. 2021;113(1):S82–87. doi: 10.1016/j.ijid.2021.02.090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Agusto F.B. Optimal isolation control strategies and cost-effectiveness analysis of a two-strain avian influenza model. Biosystems. 2013;113(3):155–164. doi: 10.1016/j.biosystems.2013.06.004. [DOI] [PubMed] [Google Scholar]
  • 18.Buonomo B. Analysis of a malaria model with mosquito host choice and bed-net control. Int J Biomath. 2015;8(6) [Google Scholar]
  • 19.Zio S., Tougri I., Lamien B. 2020. Propagation du COVID19 au burkina faso, modelisation bayesienne et quantification des incertitudes: premiere approche. preprint, Ecole Polytechnique de Ouagadougou (EPO) Ouagadougou. [Google Scholar]
  • 20.Okuonghae D., Aihie V. Case detection and direct observation therapy strategy (DOTS) in Nigeria: its effect on TB dynamics. J Biol Syst. 2008;16(1):1–31. [Google Scholar]
  • 21.Liu Z., Magal P., Seydi O., Webb G.F. Understanding unreported cases in the COVID-19 epidemic outbreak in wuhan, China, and the importance of major health interventions. MPDI Biol. 2020;9(50):1–12. doi: 10.3390/biology9030050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Omame A., Okuonghae D., Umana R.A., Inyama S.C. Analysis of a co-infection model fo rHPV-TB. Appl Math Model. 2020;77:881–901. [Google Scholar]
  • 23.Das D.K., Khajanchi S., Kar T.K. Transmission dynamics of tuberculosis with mupltiple reinfections. Chaos Solitons Fractals. 2020;130 [Google Scholar]
  • 24.Noor A.U., Maqbool F., Bhatti Z.A., Khan A.U. Epidemiology of CoViD-19 pandemic: Recovery and mortality ratio around the globe. Pak J Med Sci. 2020;36(COVID19-S4):S79–S84. doi: 10.12669/pjms.36.COVID19-S4.2660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.World Health Organization . World Health Organization; 2003. Treatment of tuberculosis: Guidelines for nationl programmes. [Google Scholar]
  • 26.Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266–275. doi: 10.1016/j.jinf.2020.05.046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Agusto F.B. Optimal chemoprophylaxis and treatment control strategies of a tuberculosis transmission model. World J Model Simul. 2009;5(3):163–173. [Google Scholar]
  • 28.Nicholas J.I., Adrian E.R. Estimating SARS-CoV-2 infections from deaths, confirmed cases, tests, and random surveys. Proceedings of the National Academy of Sciences (PNAS) 2021;18(31) doi: 10.1073/pnas.2103272118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Sy A.A.B., Diagne M.L., Mbaye I Seydi O. A mathematical model for the impact of public health education campaign for tuberculosis. Far East Journal of Applied Mathematics. 2018;100(2):97–138. [Google Scholar]
  • 30.Cui J., Tao X., Zhu H. An SIS infection model incorporating media coverage. Rocky Mountain J Math. 2008;38(5):1323–1334. [Google Scholar]
  • 31.Birkhoff G., Rota G.C. 4th ed. John Wiley and Sons Inc; New York: 1989. Ordinary differential equations. [Google Scholar]
  • 32.Hutson V., Schmitt K. Permanence and the dynamics of biological systems. Math Biosci. 1992;111:1–71. doi: 10.1016/0025-5564(92)90078-b. [DOI] [PubMed] [Google Scholar]
  • 33.Mukandavire Z., Gumel A.B., Garira W., Tchuenche J.M. Mathematical analysis of a model for HIV-malaria co-infection. Math Biosci Engnr. 2009;6(2):333–362. doi: 10.3934/mbe.2009.6.333. [DOI] [PubMed] [Google Scholar]
  • 34.van den Driessche P, Watmough J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math Biosci. 2002;180(1):29–48. doi: 10.1016/s0025-5564(02)00108-6. [DOI] [PubMed] [Google Scholar]
  • 35.Castillo-Chavez C., Song B. Dynamical models of tuberculosis and their applications. Math Biosci Eng. 2004;1(2):361–404. doi: 10.3934/mbe.2004.1.361. [DOI] [PubMed] [Google Scholar]
  • 36.Tchoumi S.Y., Diagne M.L., Rwezaura H., Tchuenche J.M. Malaria and COVID-19 co-dynamics: A mathematical model and optimal control. Appl Math Model. 2021;99:294–327. doi: 10.1016/j.apm.2021.06.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Diagne M.L., Rwezaura H., Tchoumi S.Y., Tchuenche J.M. A mathematical model of COVID-19 with vaccination and treatment. Comput Math Methods Med. 2021;2021 doi: 10.1155/2021/1250129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Franco N. Covid-19 Belgium: Extended SEIR-QD model with nursing homes and long-term scenarios-based forecasts. Epidemics. 2021;37 doi: 10.1016/j.epidem.2021.100490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pontryagin L., Boltyanskii V., Gamkrelidze R., Mishchenko E. John Wiley & Sons; New York, London: 1962. The mathematical theory of optimal control process, vol. 4. [Google Scholar]
  • 40.Ndii M.Z., Hadisoemarto P., Dwi Agustian D, Supriatna A.K. An analysis of Covid-19 transmission in Indonesia and Saudi Arabia. Cmm Biomath Sci. 2020;3(1):19–27. [Google Scholar]

Articles from Informatics in Medicine Unlocked are provided here courtesy of Elsevier

RESOURCES